Why the study?
Long-term management of T2D and sustaining glycemic control remains a challenge and is crucial for reducing clinical complications and economic costs.
Does a digital therapeutic platform improve and sustain glycemic control over 3 years in high-risk patients with type 2 diabetes?
Does a digital therapeutic platform improve and sustain glycemic control over 3 years in high-risk patients with type 2 diabetes?
Use of a digital therapeutic platform for diabetes management was associated with sustained reductions in average blood glucose over 3 years, with greater improvements observed in highly engaged users.
No takes yet. Share an insight, caveat, or question.
Digital platform use was associated with BG outcomes over 3 years in high-risk T2D; leaves open causal benefit versus usual care.
HERSHCOVITZ et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: